ClinicalTrials.gg
CompletedNCT01847274Updated Jun 2, 2023Results posted

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

A Phase 3 interventional study of Active comparator: Niraparib and placebo in Ovarian Neoplasms and Platinum Sensitive Ovarian Cancer, sponsored by Tesaro, Inc.. Completed at 112 sites in 15 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-02.

Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
596
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.

Enrollment
3rd of 44
596 · median 41
Started
2013
the only one that year
Phase 3
7 of 44
none open now
Registered
3rd of 44
by date
Lead sponsor
11 of 44
Tesaro, Inc.

Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2013, is one of 7 in phase 3, and was the 3rd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing niraparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gBRCAmut or a tumor with high-grade serous histology and who have responded to their most recent chemotherapy containing a platinum agent. Niraparib is an orally active PARP inhibitor. Niraparib or placebo (in a 2:1 ratio) will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI), European Quality of Life scale, 5-Dimensions (EQ-5D), and a neuropathy questionnaire. Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), and safety laboratory values.

The primary objective of this study is to evaluate efficacy of niraparib as maintenance therapy in patients who have platinum sensitive ovarian cancer as assessed by the prolongation of progression free survival (PFS).

03

Conditions studied

  • Ovarian Neoplasms
  • Platinum Sensitive Ovarian Cancer

Browse trials for

Keywords

  • ovarian cancer
  • platinum sensitive
  • gBRCAmut
  • BRCA
  • high-grade serous histology
  • PARP inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older, female, any race
  • diagnosed ovarian cancer, fallopian tube cancer or primary peritoneal cancer
  • High grade (or grade 3) serous histology or known to have gBRCAmut
  • Has received at least 2 previous courses of platinum-containing therapy, and has disease that was considered platinum sensitive following the penultimate (next to last) platinum course (more than 6 month period between penultimate platinum regimen and progression of disease)
  • Has responded to last the platinum regimen, remains in response and is enrolled on study within 8 weeks of completion of the last platinum regimen
  • 0-1
  • Adequate bone marrow, kidney and liver function

Exclusion criteria

Exclusion Criteria:

  • Known to the components of niraparib
  • Invasive cancer other than ovarian cancer within 2 years (except basal or squamous cell carcinoma of the skin that has been definitely treated)
  • Symptomatic uncontrolled
  • Is pregnant or breast feeding
  • patients
  • Known active hepatic disease
  • Prior treatment with a known PARP inhibitor
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
596 participants (actual)

Study arms

  • Active comparator
    Niraparib

    2:1 Ratio administered once daily continuously during a 28 day cycle.

    Drug: Active comparator: Niraparib

  • Placebo comparator
    Placebo

    Administered once daily continuously over a 28 day cycle.

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA)

    PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.

    Time frame: From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years 7 months and 4 days

  2. Progression-Free Survival (PFS) in Cohort With No Germline BCRA With Homologous Recombination Deficiency-positive (HRD+) Tumors (Non-gBRCAmut HRD+)

    PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.

    Time frame: From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years, 7 months and 4 days

  3. Progression-Free Survival (PFS) in Cohort With No Germline BRCA Mutation

    PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion.PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.

    Time frame: From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years, 7 months and 4 days

Secondary outcomes

  1. Time to First Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)

    The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death.

    Time frame: From date of randomization to the earliest date of first subsequent therapy or death, up to 7 years, 7 months and 4 days

  2. Time to First Subsequent Therapy in Cohort With No Germline BRCA Mutation

    The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death

    Time frame: From date of randomization to the earliest date of first subsequent therapy or death, up to 7 years, 7 months and 4 days

  3. Chemotherapy-Free Interval in Cohort With Germline BRCA Mutation (gBRCA)

    Chemotherapy-Free Interval was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment

    Time frame: From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment, up to 7 years, 7 months and 4 days

  4. Chemotherapy-Free Interval in Cohort With No Germline BRCA Mutation

    Chemotherapy-Free Interval was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment

    Time frame: From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment, up to 7 years, 7 months and 4 days

  5. Progression-Free Survival 2 in Cohort With Germline BRCA Mutation (gBRCA)

    Progression-Free Survival 2 was defined as the date of randomization in the current study to the earlier date of assessment of progression on the next anti-cancer therapy following study treatment or death due to any cause. Progression was determined by the investigator via clinical and radiographic assessment using the same criteria as used in the current study.

    Time frame: From treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause, up to 7 years, 7 months and 4 days

  6. Progression-Free Survival 2 in Cohort With No Germline BRCA Mutation

    Progression-Free Survival 2 was defined as the date of randomization in the current study to the earlier date of assessment of progression on the next anti-cancer therapy following study treatment or death due to any cause. Progression was determined by the investigator via clinical and radiographic assessment using the same criteria as used in the current study.

    Time frame: From treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause, up to 7 years, 7 months and 4 days

  7. Overall Survival in Cohort With Germline BRCA Mutation (gBRCA)

    Overall survival was defined as the date of randomization to the date of death by any cause.

    Time frame: From treatment randomization to date of death by any cause, up to 7 years, 7 months and 4 days

  8. Overall Survival in Cohort With No Germline BRCA Mutation

    Overall survival was defined as the date of randomization to the date of death by any cause.

    Time frame: From treatment randomization to date of death by any cause, up to 7 years, 7 months and 4 days

  9. Time to Second Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)

    TSST was defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death.

    Time frame: From the date of randomization to the start date of the second subsequent anti-cancer therapy, up to 7 years, 7 months and 4 days

  10. Time to Second Subsequent Therapy in Cohort With No Germline BRCA Mutation

    TSST was defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death.

    Time frame: From the date of randomization to the start date of the second subsequent anti-cancer therapy, up to 7 years, 7 months and 4 days

  11. Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 2

    Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)

  12. Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 4

    Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)

  13. Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 6

    Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)

  14. Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Post-progression

    Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Cycle 1 Day 1, Each cycle was of 28 days) and up to 7 years, 7 months and 4 days

  15. Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 2

    Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)

  16. Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 4

    Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)

  17. Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 6

    Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)

  18. Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Post-progression

    Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Day 1) and up to 7 years, 7 months and 4 days

  19. Change From Baseline in European Quality of Life Scale, 5-Dimensions (EQ-5D-5L) in Cohort With Germline BRCA at Cycle 2

    EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)

  20. Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 4

    EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)

  21. Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 6

    EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)

  22. Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Post-progression

    EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Day 1) and up to 7 years, 7 months and 4 days

  23. Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 2

    EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)

  24. Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 4

    EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)

  25. Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 6

    EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)

  26. Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Post-progression

    EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose on Day 1) and up to 7 years, 7 months and 4 days

  27. Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Baseline

    A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit"). Baseline was latest non-missing pre-dose assessment on or before randomization date.

    Time frame: At Baseline

  28. Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Cycle 2

    A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

    Time frame: At Cycle 2 (Each cycle was of 28 days)

  29. Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Cycle 4

    A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

    Time frame: At Cycle 4 (Each cycle was of 28 days)

  30. Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Cycle 6

    A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

    Time frame: At Cycle 6 (Each cycle was of 28 days)

  31. Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Post-progression

    A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

    Time frame: Up to 7 years, 7 months and 4 days

  32. Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Baseline

    A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit"). Baseline was latest non-missing pre-dose assessment on or before randomization date.

    Time frame: At Baseline

  33. Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Cycle 2

    A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

    Time frame: At Cycle 2 (Each cycle was of 28 days)

  34. Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Cycle 4

    A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

    Time frame: At Cycle 4 (Each cycle was of 28 days)

  35. Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Cycle 6

    A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

    Time frame: At Cycle 6 (Each cycle was of 28 days)

  36. Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Post-progression

    A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

    Time frame: Up to 7 years, 7 months and 4 days

  37. Number of Participants With Concordance of a Candidate Companion BRAC Analysis Diagnostic Test Compared to the Centralized BRCA Mutation Test Used in This Study

    This will never be analyzed since the data for the candidate companion BRAC analysis diagnostic test was not collected which was to be compared with centralized BRCA mutation test used in this study.

    Time frame: Up to 7 years, 7 months and 4 days

  38. Number of Participants With Concordance of a Candidate Companion HRD Diagnostic Test Compared to the HRD Test Used in This Study

    This will never be analyzed since the data for the candidate companion HRD diagnostic test was not collected which was to be compared with HRD test used in this study.

    Time frame: Up to 7 years, 7 months and 4 days

  39. Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events. Data presented for this outcome measure is based on the data cut-off date of 31-March-2021, which aligns with the time of the study unblinding.

    Time frame: Up to 7 years, 7 months and 6 days

  40. Number of Participants With Non-serious AEs and SAEs (Post-study Unblinding)

    An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events. The data is presented for post-study unblinding duration 01-Apr-2021 to 26-Dec-2021

    Time frame: Up to 8 months, 26 days

  41. Number of Participants With Non-serious AEs and SAEs in FE Sub-study

    An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.

    Time frame: Up to 2 years, 3 months and 11 days

  42. Number of Participants With Non-serious AEs and SAEs in QTc Sub-study

    An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.

    Time frame: Up to 5 years 10 months and 22 days

  43. Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC[0-infinity]) Following Administration of Niraparib (FE Sub-study)

    Blood samples were collected at indicated time points to analyze AUC(0-infinity) of niraparib.

    Time frame: Pre-dose and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose

  44. Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUC[0-last]) Following Administration of Niraparib (FE Sub-study)

    Blood samples were collected at indicated time points to analyze the AUC(0-last) of niraparib.

    Time frame: Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose

  45. Maximum Observed Plasma Concentration (Cmax) Following Administration of Niraparib (FE Sub-study)

    Blood samples were collected at indicated time points to analyze the maximum observed plasma concentration of niraparib.

    Time frame: Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose

  46. Time to Reach Maximum (Tmax) Following Administration of Niraparib (FE Sub-study)

    Blood samples were collected at indicated time points to analyze the tmax of niraparib.

    Time frame: Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose

  47. Terminal Elimination Half-life (t1/2) Following Administration of Niraparib (FE Sub-study)

    Blood samples were collected at indicated time points to analyze the t1/2 of niraparib.

    Time frame: Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose

  48. Number of Participants With Maximum Post-Baseline QT Interval Corrected by Fridericia's Formula (QTcF) Greater Than Pre-specified Thresholds

    12-lead electrocardiogram was obtained at indicated time points using an automated electrocardiogram machine that measured QTcF interval. The number of participants with maximum post-Baseline ECG value exceeding the following limits have been reported: QTcF interval \>450 and \<= 480 milliseconds (msec) and \>500 msec.

    Time frame: At Baseline (Cycle 1 Day 1, each cycle was of 28 days)

07

Results

Posted May 1, 2019

Participant flow

This was a randomized, double-blind study conducted to analyze maintenance with niraparib versus placebo in participants with ovarian cancer.

Main Study (Upto 7years 7months 6 Days)
Participant flow — Main Study (Upto 7years 7months 6 Days)
MilestonegBRCA NiraparibgBRCA PlaceboNon-gBRCA NiraparibNon-gBRCA PlaceboFE Sub-study: Fasted/FedFE Sub-study: Fed/FastedQTc Sub-study: NiraparibgBRCA Niraparib (Post-study Unblinding [PSU])gBRCA Placebo (PSU)Non-gBRCA Niraparib (PSU)Non-gBRCA Placebo (PSU)
Started138652341160000000
Completed00000000000
Not completed138652341160000000
Withdrew: Ongoing at the time of analysis22831130000000
Withdrew: Withdrawal by subject201129140000000
Withdrew: Lost to follow-up72510000000
Withdrew: Disease progression00020000000
Withdrew: Subject unblinded by sponsor121215140000000
Withdrew: Death7229146680000000
Withdrew: Other reasons53840000000
FE Sub-study, Period1 (Day1)
Participant flow — FE Sub-study, Period1 (Day1)
MilestonegBRCA NiraparibgBRCA PlaceboNon-gBRCA NiraparibNon-gBRCA PlaceboFE Sub-study: Fasted/FedFE Sub-study: Fed/FastedQTc Sub-study: NiraparibgBRCA Niraparib (Post-study Unblinding [PSU])gBRCA Placebo (PSU)Non-gBRCA Niraparib (PSU)Non-gBRCA Placebo (PSU)
Started00008900000
Completed00008800000
Not completed00000100000
Withdrew: Adverse event00000100000
FE Sub-study, Washout 1 (Up to Day 7)
Participant flow — FE Sub-study, Washout 1 (Up to Day 7)
MilestonegBRCA NiraparibgBRCA PlaceboNon-gBRCA NiraparibNon-gBRCA PlaceboFE Sub-study: Fasted/FedFE Sub-study: Fed/FastedQTc Sub-study: NiraparibgBRCA Niraparib (Post-study Unblinding [PSU])gBRCA Placebo (PSU)Non-gBRCA Niraparib (PSU)Non-gBRCA Placebo (PSU)
Started00008800000
Completed00007800000
Not completed00001000000
Withdrew: Transferred to other arm/group00001000000
FE Sub-study, Period 2 (Day 1)
Participant flow — FE Sub-study, Period 2 (Day 1)
MilestonegBRCA NiraparibgBRCA PlaceboNon-gBRCA NiraparibNon-gBRCA PlaceboFE Sub-study: Fasted/FedFE Sub-study: Fed/FastedQTc Sub-study: NiraparibgBRCA Niraparib (Post-study Unblinding [PSU])gBRCA Placebo (PSU)Non-gBRCA Niraparib (PSU)Non-gBRCA Placebo (PSU)
Started00007800000
Completed00007800000
Not completed00000000000
QTcSub-study(Upto 5 Year,10 Month,22day)
Participant flow — QTcSub-study(Upto 5 Year,10 Month,22day)
MilestonegBRCA NiraparibgBRCA PlaceboNon-gBRCA NiraparibNon-gBRCA PlaceboFE Sub-study: Fasted/FedFE Sub-study: Fed/FastedQTc Sub-study: NiraparibgBRCA Niraparib (Post-study Unblinding [PSU])gBRCA Placebo (PSU)Non-gBRCA Niraparib (PSU)Non-gBRCA Placebo (PSU)
Started000000260000
Completed00000000000
Not completed000000260000
Withdrew: Withdrawal by subject00000040000
Withdrew: Death00000050000
Withdrew: Other reasons000000170000
Main Study PSU (Up to 8months, 26days)
Participant flow — Main Study PSU (Up to 8months, 26days)
MilestonegBRCA NiraparibgBRCA PlaceboNon-gBRCA NiraparibNon-gBRCA PlaceboFE Sub-study: Fasted/FedFE Sub-study: Fed/FastedQTc Sub-study: NiraparibgBRCA Niraparib (Post-study Unblinding [PSU])gBRCA Placebo (PSU)Non-gBRCA Niraparib (PSU)Non-gBRCA Placebo (PSU)
Started00000002283113
Completed00000000000
Not completed00000002283113
Withdrew: Subject unblinded by sponsor00000001581812
Withdrew: Subject moved to rollover study00000006090
Withdrew: Other reasons00000001031
Withdrew: Withdrawal by subject00000000010

Outcome measures

PrimaryProgression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA)

PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.

Time frame:
From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years 7 months and 4 days
Reported as:
Median · months
Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA)
monthsgBRCA NiraparibgBRCA Placebo
Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA)21 (12.9 to NA)5.5 (3.8 to 7.2)
Statistical analysis
  • gBRCA Niraparib vs gBRCA Placebo · Log Rank · p = <0.0001 (Two-sided P-value. PFS was independently evaluated in gBRCAmut cohort and non-gBRCAmut cohort.) · Hazard ratio (hr): 0.27 · 95% CI 0.173 to 0.410Niraparib:Placebo, based on the stratified Cox Proportional Hazards Model using randomization stratification factors.
PrimaryProgression-Free Survival (PFS) in Cohort With No Germline BCRA With Homologous Recombination Deficiency-positive (HRD+) Tumors (Non-gBRCAmut HRD+)

PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.

Time frame:
From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years, 7 months and 4 days
Reported as:
Median · months
Progression-Free Survival (PFS) in Cohort With No Germline BCRA With Homologous Recombination Deficiency-positive (HRD+) Tumors (Non-gBRCAmut HRD+)
monthsNon-gBRCAmut HRD+ NiraparibNon-gBRCAmut HRD+ Placebo
Progression-Free Survival (PFS) in Cohort With No Germline BCRA With Homologous Recombination Deficiency-positive (HRD+) Tumors (Non-gBRCAmut HRD+)12.9 (8.1 to 15.9)3.8 (3.5 to 5.7)
Statistical analysis
  • Non-gBRCAmut HRD+ Niraparib vs Non-gBRCAmut HRD+ Placebo · Log Rank · p = <0.0001 (Two-sided P-value. PFS was independently evaluated in gBRCAmut cohort and non-gBRCAmut cohort. Hierarchical testing: HRD+ subset tested first. If HRD+ subset demonstrated statistical significance, overall non-gBRCA cohort was then tested) · Hazard ratio (hr): 0.38 · 95% CI 0.243 to 0.586Niraparib:Placebo, based on the stratified Cox Proportional Hazards Model using randomization stratification factors.
PrimaryProgression-Free Survival (PFS) in Cohort With No Germline BRCA Mutation

PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion.PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.

Time frame:
From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years, 7 months and 4 days
Reported as:
Median · Months
Progression-Free Survival (PFS) in Cohort With No Germline BRCA Mutation
MonthsNon-gBRCA NiraparibNon-gBRCA Placebo
Progression-Free Survival (PFS) in Cohort With No Germline BRCA Mutation9.3 (7.2 to 11.2)3.9 (3.7 to 5.5)
Statistical analysis
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Log Rank · p = <0.0001 (Two-sided P-value. PFS was independently evaluated in gBRCAmut cohort and non-gBRCAmut cohort. Hierarchical testing: HRD+ subset tested first. If HRD+ subset demonstrated statistical significance, overall non-gBRCA cohort was then tested.) · Hazard ratio (hr): 0.45 · 95% CI 0.338 to 0.607Niraparib:Placebo, based on the stratified Cox Proportional Hazards Model using randomization stratification factors.
SecondaryTime to First Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)

The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death.

Time frame:
From date of randomization to the earliest date of first subsequent therapy or death, up to 7 years, 7 months and 4 days
Reported as:
Median · Months
Time to First Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)
MonthsgBRCA NiraparibgBRCA Placebo
Time to First Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)19.1 (14.6 to 21.9)8.6 (6.9 to 12.2)
Statistical analysis
  • gBRCA Niraparib vs gBRCA Placebo · Log Rank · p = 0.0005 (Two-sided p-value) · Hazard ratio (hr): 0.57 · 95% CI 0.412 to 0.783
SecondaryTime to First Subsequent Therapy in Cohort With No Germline BRCA Mutation

The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death

Time frame:
From date of randomization to the earliest date of first subsequent therapy or death, up to 7 years, 7 months and 4 days
Reported as:
Median · Months
Time to First Subsequent Therapy in Cohort With No Germline BRCA Mutation
MonthsNon-gBRCA NiraparibNon-gBRCA Placebo
Time to First Subsequent Therapy in Cohort With No Germline BRCA Mutation12.4 (10.9 to 14.5)7.4 (5.9 to 8.7)
Statistical analysis
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Log Rank · p = <0.0001 (Two-sided P-value.) · Hazard ratio (hr): 0.58 · 95% CI 0.454 to 0.740
SecondaryChemotherapy-Free Interval in Cohort With Germline BRCA Mutation (gBRCA)

Chemotherapy-Free Interval was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment

Time frame:
From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment, up to 7 years, 7 months and 4 days
Reported as:
Median · Months
Chemotherapy-Free Interval in Cohort With Germline BRCA Mutation (gBRCA)
MonthsgBRCA NiraparibgBRCA Placebo
Chemotherapy-Free Interval in Cohort With Germline BRCA Mutation (gBRCA)20.0 (16.2 to 23.3)9.4 (7.9 to 10.4)
Statistical analysis
  • gBRCA Niraparib vs gBRCA Placebo · Log Rank · p = <0.0001 (Two-sided P-value.) · Hazard ratio (hr): 0.39 · 95% CI 0.268 to 0.561
SecondaryChemotherapy-Free Interval in Cohort With No Germline BRCA Mutation

Chemotherapy-Free Interval was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment

Time frame:
From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment, up to 7 years, 7 months and 4 days
Reported as:
Median · Months
Chemotherapy-Free Interval in Cohort With No Germline BRCA Mutation
MonthsNon-gBRCA NiraparibNon-gBRCA Placebo
Chemotherapy-Free Interval in Cohort With No Germline BRCA Mutation13.4 (11.3 to 14.8)8.7 (6.9 to 10.0)
Statistical analysis
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Log Rank · p = <0.0001 (Two-sided P-value.) · Hazard ratio (hr): 0.56 · 95% CI 0.428 to 0.727
SecondaryProgression-Free Survival 2 in Cohort With Germline BRCA Mutation (gBRCA)

Progression-Free Survival 2 was defined as the date of randomization in the current study to the earlier date of assessment of progression on the next anti-cancer therapy following study treatment or death due to any cause. Progression was determined by the investigator via clinical and radiographic assessment using the same criteria as used in the current study.

Time frame:
From treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause, up to 7 years, 7 months and 4 days
Reported as:
Median · Months
Progression-Free Survival 2 in Cohort With Germline BRCA Mutation (gBRCA)
MonthsgBRCA NiraparibgBRCA Placebo
Progression-Free Survival 2 in Cohort With Germline BRCA Mutation (gBRCA)29.9 (24.8 to 33.4)22.7 (19.5 to 25.9)
Statistical analysis
  • gBRCA Niraparib vs gBRCA Placebo · Log Rank · p = 0.0302 (Two-sided P-value.) · Hazard ratio (hr): 0.70 · 95% CI 0.500 to 0.968
SecondaryProgression-Free Survival 2 in Cohort With No Germline BRCA Mutation

Progression-Free Survival 2 was defined as the date of randomization in the current study to the earlier date of assessment of progression on the next anti-cancer therapy following study treatment or death due to any cause. Progression was determined by the investigator via clinical and radiographic assessment using the same criteria as used in the current study.

Time frame:
From treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause, up to 7 years, 7 months and 4 days
Reported as:
Median · Months
Progression-Free Survival 2 in Cohort With No Germline BRCA Mutation
MonthsNon-gBRCA NiraparibNon-gBRCA Placebo
Progression-Free Survival 2 in Cohort With No Germline BRCA Mutation19.5 (17.1 to 22.3)16.1 (13.6 to 22.8)
Statistical analysis
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Log Rank · p = 0.0748 (Two-sided P-value.) · Hazard ratio (hr): 0.80 · 95% CI 0.627 to 1.022
SecondaryOverall Survival in Cohort With Germline BRCA Mutation (gBRCA)

Overall survival was defined as the date of randomization to the date of death by any cause.

Time frame:
From treatment randomization to date of death by any cause, up to 7 years, 7 months and 4 days
Reported as:
Median · Months
Overall Survival in Cohort With Germline BRCA Mutation (gBRCA)
MonthsgBRCA NiraparibgBRCA Placebo
Overall Survival in Cohort With Germline BRCA Mutation (gBRCA)40.9 (34.9 to 52.9)38.1 (27.6 to 47.3)
Statistical analysis
  • gBRCA Niraparib vs gBRCA Placebo · Log Rank · p = 0.3580 (Two-sided P-value.) · Hazard ratio (hr): 0.85 · 95% CI 0.606 to 1.198
SecondaryOverall Survival in Cohort With No Germline BRCA Mutation

Overall survival was defined as the date of randomization to the date of death by any cause.

Time frame:
From treatment randomization to date of death by any cause, up to 7 years, 7 months and 4 days
Reported as:
Median · Months
Overall Survival in Cohort With No Germline BRCA Mutation
MonthsNon-gBRCA NiraparibNon-gBRCA Placebo
Overall Survival in Cohort With No Germline BRCA Mutation31.0 (27.8 to 35.6)34.8 (27.9 to 41.4)
Statistical analysis
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Log Rank · p = 0.6868 (Two-sided P-value.) · Hazard ratio (hr): 1.06 · 95% CI 0.813 to 1.369
SecondaryTime to Second Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)

TSST was defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death.

Time frame:
From the date of randomization to the start date of the second subsequent anti-cancer therapy, up to 7 years, 7 months and 4 days
Reported as:
Median · Months
Time to Second Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)
MonthsgBRCA NiraparibgBRCA Placebo
Time to Second Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)29.7 (23.3 to 33.4)19.6 (14.4 to 25.5)
Statistical analysis
  • gBRCA Niraparib vs gBRCA Placebo · Log Rank · p = 0.0061 (Two-sided P-value.) · Hazard ratio (hr): 0.63 · 95% CI 0.451 to 0.878
SecondaryTime to Second Subsequent Therapy in Cohort With No Germline BRCA Mutation

TSST was defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death.

Time frame:
From the date of randomization to the start date of the second subsequent anti-cancer therapy, up to 7 years, 7 months and 4 days
Reported as:
Median · Months
Time to Second Subsequent Therapy in Cohort With No Germline BRCA Mutation
MonthsNon-gBRCA NiraparibNon-gBRCA Placebo
Time to Second Subsequent Therapy in Cohort With No Germline BRCA Mutation20.3 (18.0 to 23.4)16.7 (14.9 to 21.3)
Statistical analysis
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Log Rank · p = 0.1674 (Two-sided P-value.) · Hazard ratio (hr): 0.84 · 95% CI 0.654 to 1.077
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 2

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)
Reported as:
Mean · Scores on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 2
Scores on a scalegBRCA NiraparibgBRCA Placebo
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 2-0.8 ± 4.58-0.3 ± 3.19
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 4

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)
Reported as:
Mean · Scores on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 4
Scores on a scalegBRCA NiraparibgBRCA Placebo
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 4-0.1 ± 4.07-0.3 ± 3.88
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 6

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)
Reported as:
Mean · Scores on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 6
Scores on a scalegBRCA NiraparibgBRCA Placebo
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 60.5 ± 3.77-0.5 ± 4.27
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Post-progression

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Cycle 1 Day 1, Each cycle was of 28 days) and up to 7 years, 7 months and 4 days
Reported as:
Mean · Scores on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Post-progression
Scores on a scalegBRCA NiraparibgBRCA Placebo
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Post-progression-0.751 ± 4.4342-1.324 ± 4.5034
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 2

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)
Reported as:
Mean · Scores on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 2
Scores on a scaleNon-gBRCA NiraparibNon-gBRCA Placebo
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 2-1.0 ± 3.79-0.3 ± 2.84
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 4

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)
Reported as:
Mean · Scores on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 4
Scores on a scaleNon-gBRCA NiraparibNon-gBRCA Placebo
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 4-0.7 ± 4.16-0.9 ± 4.23
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 6

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)
Reported as:
Mean · Scores on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 6
Scores on a scaleNon-gBRCA NiraparibNon-gBRCA Placebo
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 6-0.2 ± 3.76-0.9 ± 3.43
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Post-progression

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Day 1) and up to 7 years, 7 months and 4 days
Reported as:
Mean · Scores on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Post-progression
Scores on a scaleNon-gBRCA NiraparibNon-gBRCA Placebo
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Post-progression-2.595 ± 5.5700-1.801 ± 4.0290
SecondaryChange From Baseline in European Quality of Life Scale, 5-Dimensions (EQ-5D-5L) in Cohort With Germline BRCA at Cycle 2

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)
Reported as:
Mean · Scores on a scale
Change From Baseline in European Quality of Life Scale, 5-Dimensions (EQ-5D-5L) in Cohort With Germline BRCA at Cycle 2
Scores on a scalegBRCA NiraparibgBRCA Placebo
Change From Baseline in European Quality of Life Scale, 5-Dimensions (EQ-5D-5L) in Cohort With Germline BRCA at Cycle 2-0.008 ± 0.1092-0.008 ± 0.1354
SecondaryChange From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 4

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 4
Scores on a scalegBRCA NiraparibgBRCA Placebo
Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 4-0.010 ± 0.1225-0.035 ± 0.1156
SecondaryChange From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 6

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 6
Scores on a scalegBRCA NiraparibgBRCA Placebo
Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 60.002 ± 0.1116-0.004 ± 0.1463
SecondaryChange From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Post-progression

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Day 1) and up to 7 years, 7 months and 4 days
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Post-progression
Scores on a scalegBRCA NiraparibgBRCA Placebo
Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Post-progression-0.041 ± 0.1192-0.013 ± 0.1580
SecondaryChange From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 2

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 2
Scores on a scaleNon-gBRCA NiraparibNon-gBRCA Placebo
Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 2-0.007 ± 0.1013-0.011 ± 0.1015
SecondaryChange From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 4

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 4
Scores on a scaleNon-gBRCA NiraparibNon-gBRCA Placebo
Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 4-0.004 ± 0.1077-0.014 ± 0.0870
SecondaryChange From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 6

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 6
Scores on a scaleNon-gBRCA NiraparibNon-gBRCA Placebo
Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 60.005 ± 0.1097-0.011 ± 0.0949
SecondaryChange From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Post-progression

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose on Day 1) and up to 7 years, 7 months and 4 days
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Post-progression
Scores on a scaleNon-gBRCA NiraparibNon-gBRCA Placebo
Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Post-progression-0.047 ± 0.1355-0.050 ± 0.1351
SecondaryNumber of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Baseline

A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit"). Baseline was latest non-missing pre-dose assessment on or before randomization date.

Time frame:
At Baseline
Reported as:
Count of participants · Participants
Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Baseline
ParticipantsgBRCA NiraparibgBRCA Placebo
Feet, 0-Not at all4726
Feet, 1-A little bit3212
Feet, 2-Somewhat249
Feet, 3-Quite a bit2110
Feet, 4-Very much96
Hands, 0-Not at all8037
Hands, 1-A little bit2813
Hands, 2-Somewhat86
Hands, 3-Quite a bit145
Hands, 4-Very much32
Statistical analysis
  • gBRCA Niraparib vs gBRCA Placebo · Pearson's Chi-squared test · p = 0.7969Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet
  • gBRCA Niraparib vs gBRCA Placebo · Pearson's Chi-squared test · p = 0.8794Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands
SecondaryNumber of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Cycle 2

A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

Time frame:
At Cycle 2 (Each cycle was of 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Cycle 2
ParticipantsgBRCA NiraparibgBRCA Placebo
Feet, 0-Not at all4825
Feet, 1-A little bit225
Feet, 2-Somewhat1715
Feet, 3-Quite a bit2010
Feet, 4-Very much83
Hands, 0-Not at all7331
Hands, 1-A little bit1916
Hands, 2-Somewhat136
Hands, 3-Quite a bit72
Hands, 4-Very much32
Statistical analysis
  • gBRCA Niraparib vs gBRCA Placebo · Pearson's Chi-squared test · p = 0.2399Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet
  • gBRCA Niraparib vs gBRCA Placebo · Pearson's Chi-squared test · p = 0.4584Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands
SecondaryNumber of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Cycle 4

A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

Time frame:
At Cycle 4 (Each cycle was of 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Cycle 4
ParticipantsgBRCA NiraparibgBRCA Placebo
Feet, 0-Not at all4720
Feet, 1-A little bit226
Feet, 2-Somewhat207
Feet, 3-Quite a bit158
Feet, 4-Very much62
Hands, 0-Not at all7029
Hands, 1-A little bit186
Hands, 2-Somewhat163
Hands, 3-Quite a bit44
Hands, 4-Very much21
Statistical analysis
  • gBRCA Niraparib vs gBRCA Placebo · Pearson's Chi-squared test · p = 0.8566Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet
  • gBRCA Niraparib vs gBRCA Placebo · Pearson's Chi-squared test · p = 0.4705Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands
SecondaryNumber of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Cycle 6

A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

Time frame:
At Cycle 6 (Each cycle was of 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Cycle 6
ParticipantsgBRCA NiraparibgBRCA Placebo
Feet, 0-Not at all4417
Feet, 1-A little bit175
Feet, 2-Somewhat137
Feet, 3-Quite a bit155
Feet, 4-Very much92
Hands, 0-Not at all5421
Hands, 1-A little bit258
Hands, 2-Somewhat104
Hands, 3-Quite a bit62
Hands, 4-Very much21
Statistical analysis
  • gBRCA Niraparib vs gBRCA Placebo · Pearson's Chi-squared test · p = 0.8521Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet
  • gBRCA Niraparib vs gBRCA Placebo · Pearson's Chi-squared test · p = 0.9923Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands
SecondaryNumber of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Post-progression

A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

Time frame:
Up to 7 years, 7 months and 4 days
Reported as:
Count of participants · Participants
Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Post-progression
ParticipantsgBRCA NiraparibgBRCA Placebo
Feet, 0-Not at all3115
Feet, 1-A little bit209
Feet, 2-Somewhat73
Feet, 3-Quite a bit157
Feet, 4-Very much73
Hands, 0-Not at all4426
Hands, 1-A little bit184
Hands, 2-Somewhat83
Hands, 3-Quite a bit74
Hands, 4-Very much30
Statistical analysis
  • gBRCA Niraparib vs gBRCA Placebo · Pearson's Chi-squared test · p = 0.9997Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet
  • gBRCA Niraparib vs gBRCA Placebo · Pearson's Chi-squared test · p = 0.3518Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands
SecondaryNumber of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Baseline

A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit"). Baseline was latest non-missing pre-dose assessment on or before randomization date.

Time frame:
At Baseline
Reported as:
Count of participants · Participants
Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Baseline
ParticipantsNon-gBRCA NiraparibNon-gBRCA Placebo
Feet, 0-Not at all7140
Feet, 1-A little bit5826
Feet, 2-Somewhat3716
Feet, 3-Quite a bit4321
Feet, 4-Very much189
Hands, 0-Not at all12048
Hands, 1-A little bit5637
Hands, 2-Somewhat2812
Hands, 3-Quite a bit1511
Hands, 4-Very much82
Statistical analysis
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Pearson's Chi-squared test · p = 0.9367Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Pearson's Chi-squared test · p = 0.2502Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands
SecondaryNumber of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Cycle 2

A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

Time frame:
At Cycle 2 (Each cycle was of 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Cycle 2
ParticipantsNon-gBRCA NiraparibNon-gBRCA Placebo
Feet, 0-Not at all6932
Feet, 1-A little bit3917
Feet, 2-Somewhat3012
Feet, 3-Quite a bit3418
Feet, 4-Very much98
Hands, 0-Not at all10044
Hands, 1-A little bit3824
Hands, 2-Somewhat2019
Hands, 3-Quite a bit175
Hands, 4-Very much43
Statistical analysis
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Pearson's Chi-squared test · p = 0.5037Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Pearson's Chi-squared test · p = 0.1640Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands
SecondaryNumber of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Cycle 4

A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

Time frame:
At Cycle 4 (Each cycle was of 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Cycle 4
ParticipantsNon-gBRCA NiraparibNon-gBRCA Placebo
Feet, 0-Not at all5431
Feet, 1-A little bit3716
Feet, 2-Somewhat3417
Feet, 3-Quite a bit2011
Feet, 4-Very much95
Hands, 0-Not at all8943
Hands, 1-A little bit2921
Hands, 2-Somewhat1410
Hands, 3-Quite a bit143
Hands, 4-Very much61
Statistical analysis
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Pearson's Chi-squared test · p = 0.9599Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Pearson's Chi-squared test · p = 0.2470Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands
SecondaryNumber of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Cycle 6

A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

Time frame:
At Cycle 6 (Each cycle was of 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Cycle 6
ParticipantsNon-gBRCA NiraparibNon-gBRCA Placebo
Feet, 0-Not at all4316
Feet, 1-A little bit2910
Feet, 2-Somewhat3011
Feet, 3-Quite a bit189
Feet, 4-Very much55
Hands, 0-Not at all6829
Hands, 1-A little bit3010
Hands, 2-Somewhat136
Hands, 3-Quite a bit95
Hands, 4-Very much30
Statistical analysis
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Pearson's Chi-squared test · p = 0.5921Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Pearson's Chi-squared test · p = 0.7459Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands
SecondaryNumber of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Post-progression

A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").

Time frame:
Up to 7 years, 7 months and 4 days
Reported as:
Count of participants · Participants
Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Post-progression
ParticipantsNon-gBRCA NiraparibNon-gBRCA Placebo
Feet, 0-Not at all5732
Feet, 1-A little bit4512
Feet, 2-Somewhat2316
Feet, 3-Quite a bit1916
Feet, 4-Very much58
Hands, 0-Not at all8848
Hands, 1-A little bit3515
Hands, 2-Somewhat139
Hands, 3-Quite a bit710
Hands, 4-Very much31
Statistical analysis
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Pearson's Chi-squared test · p = 0.0259
  • Non-gBRCA Niraparib vs Non-gBRCA Placebo · Pearson's Chi-squared test · p = 0.2798Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands
SecondaryNumber of Participants With Concordance of a Candidate Companion BRAC Analysis Diagnostic Test Compared to the Centralized BRCA Mutation Test Used in This Study

This will never be analyzed since the data for the candidate companion BRAC analysis diagnostic test was not collected which was to be compared with centralized BRCA mutation test used in this study.

Time frame:
Up to 7 years, 7 months and 4 days

No measurements were reported for this outcome.

SecondaryNumber of Participants With Concordance of a Candidate Companion HRD Diagnostic Test Compared to the HRD Test Used in This Study

This will never be analyzed since the data for the candidate companion HRD diagnostic test was not collected which was to be compared with HRD test used in this study.

Time frame:
Up to 7 years, 7 months and 4 days

No measurements were reported for this outcome.

SecondaryNumber of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs)

An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events. Data presented for this outcome measure is based on the data cut-off date of 31-March-2021, which aligns with the time of the study unblinding.

Time frame:
Up to 7 years, 7 months and 6 days
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs)
ParticipantsgBRCA NiraparibgBRCA PlaceboNon-gBRCA NiraparibNon-gBRCA Placebo
Non-serious AEs13662231110
SAEs5197620
SecondaryNumber of Participants With Non-serious AEs and SAEs (Post-study Unblinding)

An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events. The data is presented for post-study unblinding duration 01-Apr-2021 to 26-Dec-2021

Time frame:
Up to 8 months, 26 days
Reported as:
Count of participants · Participants
Number of Participants With Non-serious AEs and SAEs (Post-study Unblinding)
ParticipantsgBRCA Niraparib (PSU)gBRCA Placebo (PSU)Non-gBRCA Niraparib (PSU)Non-gBRCA Placebo (PSU)
Non-serious AEs0000
SAEs0000
SecondaryNumber of Participants With Non-serious AEs and SAEs in FE Sub-study

An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.

Time frame:
Up to 2 years, 3 months and 11 days
Reported as:
Count of participants · Participants
Number of Participants With Non-serious AEs and SAEs in FE Sub-study
ParticipantsFE Niraparib FastedFE Niraparib Fed
Non-serious AEs46
SAEs10
SecondaryNumber of Participants With Non-serious AEs and SAEs in QTc Sub-study

An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.

Time frame:
Up to 5 years 10 months and 22 days
Reported as:
Count of participants · Participants
Number of Participants With Non-serious AEs and SAEs in QTc Sub-study
ParticipantsQTc Sub-study: Niraparib
Non-serious AEs24
SAEs12
SecondaryArea Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC[0-infinity]) Following Administration of Niraparib (FE Sub-study)

Blood samples were collected at indicated time points to analyze AUC(0-infinity) of niraparib.

Time frame:
Pre-dose and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose
Reported as:
Mean · Nanograms*hour per milliliter
Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC[0-infinity]) Following Administration of Niraparib (FE Sub-study)
Nanograms*hour per milliliterFE Niraparib FastedFE Niraparib Fed
Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC[0-infinity]) Following Administration of Niraparib (FE Sub-study)29016.1 ± 18405.2331194 ± 16894.88
Statistical analysis
  • FE Niraparib Fasted vs FE Niraparib Fed · Ratio of least square mean: 1.10 · 90% CI 0.997 to 1.216
SecondaryArea Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUC[0-last]) Following Administration of Niraparib (FE Sub-study)

Blood samples were collected at indicated time points to analyze the AUC(0-last) of niraparib.

Time frame:
Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose
Reported as:
Mean · Nanograms*hour per milliliter
Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUC[0-last]) Following Administration of Niraparib (FE Sub-study)
Nanograms*hour per milliliterFE Niraparib FastedFE Niraparib Fed
Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUC[0-last]) Following Administration of Niraparib (FE Sub-study)28638.1 ± 17911.8627186.4 ± 14111.37
Statistical analysis
  • FE Niraparib Fasted vs FE Niraparib Fed · Ratio of least square mean: 1.068 · 90% CI 0.978 to 1.166
SecondaryMaximum Observed Plasma Concentration (Cmax) Following Administration of Niraparib (FE Sub-study)

Blood samples were collected at indicated time points to analyze the maximum observed plasma concentration of niraparib.

Time frame:
Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose
Reported as:
Mean · Nanograms per milliliter
Maximum Observed Plasma Concentration (Cmax) Following Administration of Niraparib (FE Sub-study)
Nanograms per milliliterFE Niraparib FastedFE Niraparib Fed
Maximum Observed Plasma Concentration (Cmax) Following Administration of Niraparib (FE Sub-study)803.7 ± 403.35582.1 ± 228.57
Statistical analysis
  • FE Niraparib Fasted vs FE Niraparib Fed · Ratio of least square mean: 0.785 · 90% CI 0.695 to 0.886
SecondaryTime to Reach Maximum (Tmax) Following Administration of Niraparib (FE Sub-study)

Blood samples were collected at indicated time points to analyze the tmax of niraparib.

Time frame:
Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose
Reported as:
Median · Hour
Time to Reach Maximum (Tmax) Following Administration of Niraparib (FE Sub-study)
HourFE Niraparib FastedFE Niraparib Fed
Time to Reach Maximum (Tmax) Following Administration of Niraparib (FE Sub-study)3.1 (1.7 to 6.1)6.1 (1.2 to 23)
SecondaryTerminal Elimination Half-life (t1/2) Following Administration of Niraparib (FE Sub-study)

Blood samples were collected at indicated time points to analyze the t1/2 of niraparib.

Time frame:
Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose
Reported as:
Mean · Hour
Terminal Elimination Half-life (t1/2) Following Administration of Niraparib (FE Sub-study)
HourFE Niraparib FastedFE Niraparib Fed
Terminal Elimination Half-life (t1/2) Following Administration of Niraparib (FE Sub-study)50.5 ± 17.8747.9 ± 17.54
SecondaryNumber of Participants With Maximum Post-Baseline QT Interval Corrected by Fridericia's Formula (QTcF) Greater Than Pre-specified Thresholds

12-lead electrocardiogram was obtained at indicated time points using an automated electrocardiogram machine that measured QTcF interval. The number of participants with maximum post-Baseline ECG value exceeding the following limits have been reported: QTcF interval \>450 and \<= 480 milliseconds (msec) and \>500 msec.

Time frame:
At Baseline (Cycle 1 Day 1, each cycle was of 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline QT Interval Corrected by Fridericia's Formula (QTcF) Greater Than Pre-specified Thresholds
ParticipantsQTc Sub-study: Niraparib
>450 msec2
>480 msec0
>500 msec0

Adverse events

Collected over All-cause mortality, non-serious AEs (non-SAEs) and SAEs were collected up to 8 years, 6 months and 6 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
gBRCA Niraparib72/136 (52.9%)51/136 (37.5%)136/136 (100%)
gBRCA Placebo29/65 (44.6%)9/65 (13.8%)62/65 (95.4%)
Non-gBRCA Niraparib146/231 (63.2%)76/231 (32.9%)231/231 (100%)
Non-gBRCA Placebo68/114 (59.6%)20/114 (17.5%)110/114 (96.5%)
FE Niraparib Fasted0/16 (0%)1/16 (6.3%)4/16 (25%)
FE Niraparib Fed0/16 (0%)0/16 (0%)6/16 (37.5%)
QTc Sub-study: Niraparib5/26 (19.2%)12/26 (46.2%)24/26 (92.3%)
gBRCA Niraparib (Post-study Unblinding [PSU])0/22 (0%)0/22 (0%)0/22 (0%)
gBRCA Placebo (PSU)0/8 (0%)0/8 (0%)0/8 (0%)
Non-gBRCA Niraparib (PSU)0/31 (0%)0/31 (0%)0/31 (0%)
Non-gBRCA Placebo (PSU)0/13 (0%)0/13 (0%)0/13 (0%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
EventgBRCA NiraparibgBRCA PlaceboNon-gBRCA NiraparibNon-gBRCA PlaceboFE Niraparib FastedFE Niraparib FedQTc Sub-study: NiraparibgBRCA Niraparib (Post-study Unblinding [PSU])gBRCA Placebo (PSU)Non-gBRCA Niraparib (PSU)Non-gBRCA Placebo (PSU)
ThrombocytopeniaBlood and lymphatic system disorders18/1360/6523/2310/1140/160/163/260/220/80/310/12
AnaemiaBlood and lymphatic system disorders4/1360/6513/2310/1140/160/162/260/220/80/310/13
Urinary tract infectionInfections and infestations1/1361/652/2311/1141/160/161/260/220/80/310/13
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/1361/650/2310/1140/160/160/260/220/80/310/13
Small intestinal obstructionGastrointestinal disorders3/1360/656/2314/1140/160/161/260/220/80/310/13
AscitesGastrointestinal disorders2/1360/650/2312/1140/160/161/260/220/80/310/13
Abdominal painGastrointestinal disorders1/1360/651/2311/1140/160/161/260/220/80/310/13
Hip fractureInjury, poisoning and procedural complications1/1360/650/2310/1140/160/161/260/220/80/310/13
OesophagitisGastrointestinal disorders0/1360/650/2310/1140/160/161/260/220/80/310/13
Procedural complicationInjury, poisoning and procedural complications0/1360/650/2310/1140/160/161/260/220/80/310/13
Most frequent other events
Showing 10 of 86
Most frequent other events
EventgBRCA NiraparibgBRCA PlaceboNon-gBRCA NiraparibNon-gBRCA PlaceboFE Niraparib FastedFE Niraparib FedQTc Sub-study: NiraparibgBRCA Niraparib (Post-study Unblinding [PSU])gBRCA Placebo (PSU)Non-gBRCA Niraparib (PSU)Non-gBRCA Placebo (PSU)
NauseaGastrointestinal disorders106/13623/65168/23141/1140/160/1613/260/220/80/310/13
AnaemiaBlood and lymphatic system disorders74/1365/65111/2317/1141/160/1612/260/220/80/310/13
ThrombocytopeniaBlood and lymphatic system disorders13/1362/6593/2314/114——13/260/220/80/310/13
FatigueGeneral disorders66/13619/65110/23138/1140/161/1613/260/220/80/310/13
VomitingGastrointestinal disorders57/13610/6574/23121/1140/161/1610/260/220/80/310/13
ConstipationGastrointestinal disorders56/13612/6596/23123/1140/161/169/260/220/80/310/13
NeutropeniaBlood and lymphatic system disorders24/1363/6542/2313/1140/160/1610/260/220/80/310/13
HeadacheNervous system disorders52/1367/6552/23114/1140/160/165/260/220/80/310/13
Abdominal painGastrointestinal disorders34/13617/6563/23139/1140/160/167/260/220/80/310/13
Dry mouthGastrointestinal disorders19/1362/619/2315/1140/160/160/260/22—0/310/13

Baseline characteristics

The baseline analysis population was the intent-to-treat population, defined as all randomized participants with participants analyzed according to the study drug assigned via randomization

Age, Customized
Age, Customized(Participants)gBRCA NiraparibgBRCA PlaceboNon-gBRCA NiraparibNon-gBRCA PlaceboFE Sub-study: Fasted/FedFE Sub-study: Fed/FastedQTc Sub-study: NiraparibTotal
<=18 years00000000
Between 18 and 64 years11049130695516384
>=65 years2816104473410212
Sex: Female, Male
Sex: Female, Male(Participants)gBRCA NiraparibgBRCA PlaceboNon-gBRCA NiraparibNon-gBRCA PlaceboFE Sub-study: Fasted/FedFE Sub-study: Fed/FastedQTc Sub-study: NiraparibTotal
Female138652341168926596
Male00000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)gBRCA NiraparibgBRCA PlaceboNon-gBRCA NiraparibNon-gBRCA PlaceboFE Sub-study: Fasted/FedFE Sub-study: Fed/FastedQTc Sub-study: NiraparibTotal
American Indian or Alaska Native10000012
Asian2310400120
Native Hawaiian or Other Pacific Islander00001001
Black or African American114110311
White123552011016921516
Unknown or Not Reported116191000046
08

Study locations

112 sites
  • GSK Investigational Site
    Phoenix, Arizona 85013, United States
  • GSK Investigational Site
    Tucson, Arizona 85704, United States
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Palo Alto, California 94304, United States
  • GSK Investigational Site
    San Francisco, California 94109, United States
  • GSK Investigational Site
    New Haven, Connecticut 06510, United States
  • GSK Investigational Site
    Sarasota, Florida 34232, United States
  • GSK Investigational Site
    Tampa, Florida 33612, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Chicago, Illinois 60611, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46260, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Burlington, Massachusetts 01805, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55455, United States
  • GSK Investigational Site
    Rochester, Minnesota 55905, United States
  • GSK Investigational Site
    Morristown, New Jersey 07962-1956, United States
  • GSK Investigational Site
    Farmington, New Mexico 87401, United States
  • GSK Investigational Site
    Lake Success, New York 11042, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    New York, New York 10065, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • GSK Investigational Site
    Vancouver, Oregon 98684, United States
  • GSK Investigational Site
    Abington, Pennsylvania 19001-3788, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • GSK Investigational Site
    Providence, Rhode Island 02905, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Austin, Texas 78731, United States
  • GSK Investigational Site
    Dallas, Texas 75390, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    The Woodlands, Texas 77380, United States
  • GSK Investigational Site
    Graz, A-8036, Austria
  • GSK Investigational Site
    Innsbruck, A-6020, Austria
  • GSK Investigational Site
    Wien, 1090, Austria
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Kortrijk, 8500, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Liège, 4000, Belgium
  • GSK Investigational Site
    Calgary, Alberta T2N 4N2, Canada
  • GSK Investigational Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • GSK Investigational Site
    Montreal, Quebec H3T 1E2, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • GSK Investigational Site
    Aalborg, 9100, Denmark
  • GSK Investigational Site
    Copenhagen, DK-2100, Denmark
  • GSK Investigational Site
    Herlev, DK-2730, Denmark
  • GSK Investigational Site
    Odense, 5000, Denmark
  • GSK Investigational Site
    Besançon Cedex, 25030, France
  • GSK Investigational Site
    Lille, 59000, France
  • GSK Investigational Site
    Montpellier Cedex 5, 34298, France
  • GSK Investigational Site
    Nice, 06189, France
  • GSK Investigational Site
    Saint Brieuc, 22015 cedex, France
  • GSK Investigational Site
    Saint-Herblain cedex, 44805, France
  • GSK Investigational Site
    Heidelberg, Baden-Wuerttemberg 69120, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81377, Germany
  • GSK Investigational Site
    Goettingen, Niedersachsen 37075, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30177, Germany
  • GSK Investigational Site
    Duesseldorf, Nordrhein-Westfalen 40217, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45122, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45136, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01307, Germany
  • GSK Investigational Site
    Kiel, Schleswig-Holstein 24105, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Szolnok, 5004, Hungary
  • GSK Investigational Site
    Haifa, 3109601, Israel
  • GSK Investigational Site
    Holon, 58100, Israel
  • GSK Investigational Site
    Jerusalem, 91031, Israel
  • GSK Investigational Site
    Jerusalem, 91120, Israel
  • GSK Investigational Site
    Kfar-Saba, 44281, Israel
  • GSK Investigational Site
    Rehovot, 76100, Israel
  • GSK Investigational Site
    Tel Aviv, 64239, Israel
  • GSK Investigational Site
    Tel Hashomer, 52621, Israel
  • GSK Investigational Site
    Roma, Lazio 00168, Italy
  • GSK Investigational Site
    Brescia, Lombardia 25123, Italy
  • GSK Investigational Site
    Milano, Lombardia 20141, Italy
  • GSK Investigational Site
    Catania, Sicilia 95126, Italy
  • GSK Investigational Site
    MIlano, 20133, Italy
  • GSK Investigational Site
    Bergen, 5021, Norway
  • GSK Investigational Site
    Oslo, 0379, Norway
  • GSK Investigational Site
    Bialystok, 15-207, Poland
  • GSK Investigational Site
    Gdansk, 80-219, Poland
  • GSK Investigational Site
    Lodz, 94-029, Poland
  • GSK Investigational Site
    Poznan, 60-569, Poland
  • GSK Investigational Site
    Oviedo, Asturias 33011, Spain
  • GSK Investigational Site
    Barcelona, 08907, Spain
  • GSK Investigational Site
    Barcelona, 8035, Spain
  • GSK Investigational Site
    Madrid, 28033, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Palma de Mallorca, 07198, Spain
  • GSK Investigational Site
    Linköping, SE-581 85, Sweden
  • GSK Investigational Site
    Lund, SE-221 85, Sweden

Showing the first 100 of 112 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dorum A, Tinker AV, du Bois A, Gonzalez-Martin A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164. doi: 10.1056/NEJMoa1611310. Epub 2016 Oct 7. PubMed 27717299 ↗
  • Mirza MR, Lindahl G, Mahner S, Redondo A, Fabbro M, Rimel BJ, Herrstedt J, Oza AM, Canzler U, Berek JS, Gonzalez-Martin A, Follana P, Lord R, Azodi M, Estenson K, Wang Z, Li Y, Gupta D, Matulonis U, Feng B. Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. Cancer Res Commun. 2022 Nov 15;2(11):1436-1444. doi: 10.1158/2767-9764.CRC-22-0240. eCollection 2022 Nov. PubMed 36970052 ↗
  • Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. PubMed 35170751 ↗
  • Mirza MR, Benigno B, Dorum A, Mahner S, Bessette P, Barcelo IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Herraez AC, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Gynecol Oncol. 2020 Nov;159(2):442-448. doi: 10.1016/j.ygyno.2020.09.006. Epub 2020 Sep 25. PubMed 32981695 ↗
  • Matulonis UA, Walder L, Nottrup TJ, Bessette P, Mahner S, Gil-Martin M, Kalbacher E, Ledermann JA, Wenham RM, Woie K, Lau S, Marme F, Casado Herraez A, Hardy-Bessard AC, Banerjee S, Lindahl G, Benigno B, Buscema J, Travers K, Guy H, Mirza MR. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019 Dec 1;37(34):3183-3191. doi: 10.1200/JCO.19.00917. Epub 2019 Sep 16. PubMed 31518175 ↗
  • Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019 Nov 10;37(32):2968-2973. doi: 10.1200/JCO.18.02238. Epub 2019 Jun 7. PubMed 31173551 ↗
  • Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vazquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2018 Aug;19(8):1117-1125. doi: 10.1016/S1470-2045(18)30333-4. Epub 2018 Jul 17. PubMed 30026000 ↗
  • Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018 Aug 1;29(8):1784-1792. doi: 10.1093/annonc/mdy181. Erratum In: Ann Oncol. 2019 May 1;30(5):859. doi: 10.1093/annonc/mdy255. PubMed 29767688 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Apr 2016, 34 months.

Results were first posted in May 2019, 3 years after primary completion.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 34 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2013
First posted
May 6, 2013
StartActual
Jun 21, 2013
Primary completionActual
Apr 22, 2016
CompletionActual
Dec 26, 2021
Results first posted
May 1, 2019
Last update
Jun 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01847274
Lead sponsor
Tesaro, Inc.
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT), Myriad Genetics, Inc., US Oncology Research, Sarah Cannon, Cooperative Ovarian Cancer Group (COGI), Facing Our Risk of Cancer Empowered
Responsible party
Sponsor
First posted
May 6, 2013
Start date
Jun 21, 2013
Primary completion
Apr 22, 2016
Completion
Dec 26, 2021
Results posted
May 1, 2019
Last update
Jun 2, 2023

Study contacts

GSK Clinical Studies
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion